Ross Leonard S 4
4 · EyePoint Pharmaceuticals, Inc. · Filed Oct 16, 2018
Insider Transaction Report
Form 4
Ross Leonard S
Corporate Controller
Transactions
- Tax Payment
Common Stock
2018-10-12$3.23/sh−2,945$9,512→ 31,817 total - Award
Common Stock
2018-10-12+20,000→ 34,762 total
Footnotes (2)
- [F1]On October 12, 2018 (the "FDA Approval Date"), the U.S. Food and Drug Administration approved EyePoint Pharmaceutical Inc.'s (the "Company") new drug application for YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. As a result, 10,000 shares representing a previously granted performance stock unit award vested on that date. An additional 10,000 shares from this award will vest on the first anniversary of the FDA Approval Date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date.
- [F2]No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the performance stock units.